 |
 |

Bioequivalence of Levothyroxine Preparations: Industry Sponsorship and Academic Freedom-Reply
Joseph B. Martin, MD, PhD
Chancellor University of California, San Francisco
JAMA. 1997;277(15):1201.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
In Reply.
—As industry funding for university research increases in quantity and complexity, it seems inevitable that there will be occasional clashes of culture. The case involving Dr Dong and colleagues is one such unfortunate chapter in the annals of university-industry relations, annals that are otherwise filled with tales of highly innovative and productive collaborations that have delivered enormous benefit to the public and built for our nation a research and development capability that is unmatched among the nations of the world. We must view incidents such as that involving Dong and colleagues as only temporary setbacks and learn from them how we can make our relationships more harmonious and mutually productive. Even the smallest lessons we all continue to learn are too important to ignore.
Let me make one comment in response to Mr Eckert's letter. He states, "As a partner in research, we have a responsibility to ensure that work
. . . [Full Text PDF of this Article]
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|